NDC 0002-3115

EMGALITY

Galcanezumab-gnlm

EMGALITY is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Eli Lilly And Company. The primary component is Galcanezumab.

• Product ID: 0002-3115_4b767820-97fe-430d-8e77-6047e82ac81e
• NDC: 0002-3115
• Product Type: Human Prescription Drug
• Proprietary Name: EMGALITY
• Generic Name: Galcanezumab-gnlm
• Dosage Form: Injection, Solution
• Route of Administration: SUBCUTANEOUS
• Marketing Start Date: 2019-06-04
• Marketing Category: BLA / BLA
• Application Number: BLA761063
• Labeler Name: Eli Lilly and Company
• Substance Name: GALCANEZUMAB
• Active Ingredient Strength: 100 mg/mL
• NDC Exclude Flag: N
• Listing Certified Through: 2021-12-31

Packaging

NDC 0002-3115-09

3 SYRINGE in 1 CARTON (0002-3115-09) > 1 mL in 1 SYRINGE (0002-3115-01)

• Marketing Start Date: 2019-06-17
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 0002-3115-09 [00002311509]

EMGALITY INJECTION, SOLUTION

• Marketing Category: BLA
• Application Number: BLA761063
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: ML
• Marketing Start Date: 2019-06-17

NDC 0002-3115-01 [00002311501]

EMGALITY INJECTION, SOLUTION

• Marketing Category: BLA
• Application Number: BLA761063
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: ML
• Marketing Start Date: 2019-06-04

Drug Details

Active Ingredients

Ingredient	Strength
GALCANEZUMAB	100 mg/mL

NDC Crossover Matching brand name "EMGALITY" or generic name "Galcanezumab-gnlm"

NDC	Brand Name	Generic Name
0002-1436	EMGALITY	galcanezumab-gnlm
0002-2377	EMGALITY	galcanezumab-gnlm
0002-3115	EMGALITY	galcanezumab-gnlm